Generic Manufacturers Try To Up Their Game As US Pressure Persists

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

With US generic drug price erosion running at double digits, 2017 is expected to be a challenging year for the generic drug sector. Manufacturers are looking increasingly to complex generics, injectables and biosimilars as an offset, but it's unclear if wins in those areas will be enough to bridge the growth divide.

The challenging US pricing environment for generic drugs appears poised to continue through 2017, presenting a long-lasting headache for manufacturers, which rely on the enormous US market to drive growth. While one of the biggest headwinds – FDA's effort to reduce the backlog of abbreviated new drug applications (ANDAs) – is normalizing, others like customer consolidation and smaller patent expiration opportunities will continue to put pressure on the business segment.

Generic drug manufacturers are looking increasingly to high barrier-to-entry products like sterile injectables, complex generics and biosimilars to drive growth,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.